Novo Nordisk Signs Agreement With Orbis Medicines to Develop Therapeutics for Cardiometabolic Diseases

07:37 AM EDT, 09/17/2026 (MT Newswires) -- Novo Nordisk (NVO) signed a strategic collaboration and license agreement with Orbis Medicines to develop oral macrocycle therapeutics for cardiometabolic diseases, Orbis said Thursday. Under the agreement, Orbis Medicines said it could receive up to $1.4 billion in upfront and potential development and commercial milestone payments, in addition to tiered royalties on future product sales. Orbis said that Novo will also make a strategic investment in the company. The company added that the partnership will use Novo's expertise in obesity and cardiometabolic disease and Orbis Medicines' AI-enabled macrocycle discovery platform.